Jump to Header Jump to Main Content Jump to Footer

PhIIILomustineTemozolomide Comb TherapyVSStandard Temozolomide Ptsw/Methylated MGMT PromoterGlioblas

Xiao-Tang Kong


A Study On:

  • Brain and Nervous System

Status:

Eligibility

Adults

Interested in joining this trial?

Official Title

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Details

This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.


Eligibility

You can join if...

Inclusion Criteria:
-Neurologic function assessment within 28 days prior to Step 2 registration
-Contrast-enhanced brain MRI within 4 days after surgery
-The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria:
-Current or planned treatment with any other investigational agents for the study cancer
-Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-History of pulmonary fibrosis

Get in touch with our study team